# A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00810147** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 209 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** BMS-708163
- **DRUG:** BMS-708163
- **DRUG:** BMS-708163
- **DRUG:** BMS-708163
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00810147
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810147, "A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00810147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*